Fungemia in Cancer Patients Undergoing Chemotherapy Versus Surgery: Risk Factors, Etiology and Outcome
- 1 January 1997
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 29 (3) , 301-304
- https://doi.org/10.3109/00365549709019047
Abstract
26 patients with fungemia and cancer treated with chemotherapy (group A) were compared to 25 patients with fungemia and cancer treated with surgery (group B), to assess differences in etiology, risk factors and outcome. Candida albicans was responsible for 42% of fungemias in group A, and for 92% of fungemias in group B (p < 0.005). Breakthrough fungemia occurring during antifungal prophylaxis appeared in 46.6% of group A vs 12% of group B (p < 0.02). There was significant difference in outcome between the groups: 20% of patients after surgery vs 7.7% of those after chemotherapy died from fungemia (p < 0.04). Most common risk factors recorded in both groups were catheter insertion and previous therapy with broad spectrum antibiotics.Keywords
This publication has 6 references indexed in Scilit:
- Epidemiology, Diagnosis, and Therapy of Fungal Infections in SurgeryInfection Control & Hospital Epidemiology, 1996
- Failure of Systemic Empirical Treatment with Amphotericin B to Prevent Candidemia in Neutropenic Patients with CancerClinical Infectious Diseases, 1996
- Importance of Candida Species Other than C. albicans as Pathogens in Oncology PatientsClinical Infectious Diseases, 1995
- A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without NeutropeniaNew England Journal of Medicine, 1994
- Candidemia in a Tertiary Care Hospital: Epidemiology, Risk Factors, and Predictors of MortalityClinical Infectious Diseases, 1992
- Hospital-Acquired CandidemiaArchives of internal medicine (1960), 1988